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ORIGINAL RESEARCH
Abstract: Aripiprazole, a novel atypical antipsychotic that acts as a partial agonist at the
dopamine D2 receptors, has been reported to be effective in the treatment of chronic
schizophrenia. However, the risks and benefits of using aripiprazole in the acute hospital
setting to treat severe psychotic disorders are unclear. This naturalistic study assessed the
effectiveness of aripiprazole monotherapy in a group of actively psychotic male patients (n = 10)
with schizophrenia who were admitted to an inner-city acute psychiatric unit. Most patients
(n = 7) responded to aripiprazole treatment, which was well tolerated and significantly
ameliorated psychotic symptoms after 2–3 weeks. Patients who responded to it could be safely
discharged on aripiprazole monotherapy. Side effects observed were mostly mild and transient,
and included extrapyramidal symptoms (n = 1) and neutropenia (n = 1). Aripiprazole also
remarkably attenuated dyskinetic movements in 1 patient with severe tardive dyskinesia,
thereby suggesting that it may be useful in the treatment of other disorders that are also
associated with dopamine dysfunction. Results showed that aripiprazole can be safely and
effectively employed in the hospital setting to treat severely psychotic patients with
schizophrenia, but further studies are required to establish the full range of adverse reactions
and therapeutic indications associated with its use.
Keywords: aripiprazole, schizophrenia, tardive dyskinesia, extrapyramidal symptoms, atypical
antipsychotics, neutropenia
Introduction
Atypical antipsychotics have replaced conventional antipsychotics as the drugs of
choice in the pharmacological treatment of schizophrenia (NICE 2002). The
distinguishing feature of most atypical antipsychotics is a higher binding affinity for
serotonin 5-HT2 than for dopamine D2 receptors (Goldstein 2000). Whether the
binding affinities of atypical antipsychotics are directly associated with their mode
of action, previous extensive research work had given rise to the dopaminergic theory
of schizophrenia, which linked the therapeutic effect of conventional antipsychotics
to the blockade of post-synaptic dopamine D2 receptors (Carlsson 1996). However,
as conventional antipsychotics indiscriminately occupy dopamine receptors, their
therapeutic effects are accompanied by a range of dopamine-related side effects,
including extrapyramidal symptoms (EPS), hyperprolactinemia, and possibly
worsening of negative symptoms of schizophrenia.
Aripiprazole is a novel atypical antipsychotic that differs from other drugs of its
class by acting as a partial agonist at the D2 receptor (McGavin and Goa 2002). It
also has partial agonist activity at 5-HT1A receptors and antagonist activity at 5-HT2A
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receptors. Aripiprazole treatment has been shown to be well
tolerated and effective in the prevention of relapse in patients
with chronic, stable schizophrenia (Pigott et al 2003). It has
also been reported to be at least as effective as haloperidol
in the long-term treatment of patients with chronic
schizophrenia following an acute relapse of their illness,
while inducing less EPS (Kasper et al 2003). Aripiprazole
has been licensed for use in the EU since 2004, but the risks
and benefits of using aripiprazole in the acute hospital setting
for the treatment of severe psychotic disorders have not been
fully ascertained. We present a small naturalistic study on
the use of aripiprazole in the acute treatment of active
psychotic symptoms in a group of adult male patients with
a diagnosis of schizophrenia who were admitted to our busy
inner-city psychiatric unit.
Method
The study was conducted in an 18-bed inner-London
specialist acute psychiatric ward that caters for male patients
aged between 18 and 65 years old suffering from severe
mental illness. Most referrals to the unit come from local
community mental health services (CMHS) and hospital
accident and emergency departments. By definition, patients
who are admitted to the unit cannot be managed clinically
by local CMHS. Most patients are compulsorily admitted
and detained in hospital, at least initially, under the England
and Wales Mental Health Act 1983. The unit has a high
admission throughput and, depending on their progress,
patients are discharged as soon as appropriate and
transferred back to CMHS. Average duration of stay is 4–6
weeks, yet up to 20% of patients may at times remain on
the ward for a few months.
This was a prospective naturalistic study, approved as a
clinical audit by the local drugs and therapeutics committee.
Ten patients who had been consecutively admitted to the
unit for assessment and treatment of an acute psychotic state,
who met the ICD-10 (WHO 1994) diagnostic criteria of
schizophrenia, and for whom the prescription of an atypical
antipsychotic was thought to be the pharmacological
treatment of choice, were considered for the study. The
diagnosis of schizophrenia was established following a
thorough clinical interview with each patient and subsequent
clinical discussion within the multidisciplinary team.
Information on patients’ psychiatric history was obtained
from their medical records, whereby the duration of their
illness could be estimated. All patients were assessed on
admission using the Brief Psychiatric Rating Scale (BPRS)
(Bech et al 1986), 18-item version, 0–4 score range per item,
0–72 total score range, an instrument that the team was
familiar with. Only patients who had scored at least 40 points
at baseline were included. We followed NICE (2002)
guidelines and discussed the choice of antipsychotic
medication with patients before treatment was initiated. All
patients underwent a physical examination and routine
investigations involving full blood count, thyroid and liver
function tests, and urinanalysis, the results of which were
within normal limits. Patients were excluded from the study
if they were receiving concomitantly other antipsychotics,
antidepressants, or mood stabilizers, and if they were known
to have abused any illicit substance during the week before
admission.
The 10 patients received therapeutic oral doses of
aripiprazole, ranging from 15 mg to 30 mg daily, for at least
4 weeks from the day of admission. After 4 weeks, patients
who failed to respond to aripiprazole could be switched to
an alternative antipsychotic. Aripiprazole treatment could
be discontinued at any time if a patient experienced any
major adverse reaction or if response to treatment was
deemed unsatisfactory. Patients could also be prescribed
lorazepam for agitation–restlessness and anticholinergic
drugs as required to treat EPS, as well as nonpsychotropic
medication if needed. Nonmedical interventions, including
occupational therapy and group activities, followed the
standard clinical procedures that apply to all patients on the
ward. Each patient receiving aripiprazole treatment was
assessed by a trained independent psychiatrist, who was not
involved in prescribing to the patients, using the BPRS on
5 weekly occasions, namely, on admission (baseline BPRS
score) and subsequently for 4 weeks, once a week on the
same day. We arbitrarily defined response to treatment as a
reduction of 20 points from each patient’s BPRS score at
baseline. We also recorded the relevant therapeutic responses
in patients as perceived by the multidisciplinary team, as
well as adverse effects of aripiprazole treatment and the final
outcome of the hospital treatment after 6 weeks for each
individual patient. Descriptive statistical analysis was used
to delineate the results and the Student’s t-test was used to
assess changes in BPRS scores.
Results
Results of the audit are shown in Table 1. Ten male patients
with a diagnosis of schizophrenia, with a median age of 36
years (range 19–50) and an estimated duration of illness
ranging from 3 months to 33 years (median 30 months; 6.5
years ± 9.1, mean ± standard deviation), were included. Six
of the patients had had previous admissions to hospital. FiveNeuropsychiatric Disease and Treatment 2006:2(2) 193
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Table 1 Aripiprazole antipsychotic monotherapy in 10 male patients with schizophrenia admitted to an inner-London acute
psychiatric unit
Patient 1 Patient 2 Patient 3 Patient 4  Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10
Age 50 43 20 47 22 38 39 24 19 34
Estimated duration
of illness 33 years 3 years 2 years 4 months 2 years 4 years 2 years 3 years 3 months 8 years
No. of previous
admissions >10 2 0 0 0 3 1 2 0 3
Comorbidity
a Asthma Alcohol Nil Poly- Poly- Obesity Nil HIV- Nil Cannabis
abuse  substance substance positive, abuse
abuse abuse and tardive
anxiety dyskinesia,
cannabis
abuse
Concurrent Lorazepam Vitamin B  Lorazepam Nil Lorazepam Lorazepam Nil Hyoscine Lorazepam Lorazepam
medication hydro-
bromide
300 mg
twice daily
Antipsychotics Risperidone Risperidone Nil Nil Risperidone Olanzapine Risperidone Risperidone, Nil Olanzapine
before Flupenthixol olanzapine,
admission decanoate haloperidol
BPRS (0–72)
Baseline 42 41 54 40 54 47 52 40 65 53
Week 1 41 11 55 13 55 50 54 30 58 43
Week 2 40 5 56 16 45 31 41 28 50 42
Week 3 41 5 59 9 44 13 48 14 51 40
Week 4b 35 2 – 6 16 11 32 – 54 29
Observed No major Paranoia No clinical Paranoid Psychotic Negative More Psychotic No Overall
therapeutic clinical resolved, change delusions symptoms symptoms interactive. symptoms noticeable good
response change improved resolved resolved. resolved. Negative and change clinical
remarkably Less More and dyskinetic response
anxious and interactive positive movements
ambivalent symptoms ameliorated
resolved
gradually
Observed Nil Nil Nil Nil Mild Nil Drowsiness Decrease Nil Nil
adverse perioral in WBC
effects involuntary (also on
movement risperidone
and
olanzapine)
Final outcome Improved Discharged  Changed to Discharged Discharged Discharged Improved  Changed to  Improved Continued
after 6 weeks
c on home, depot home, home, home, noticeably risperidone, on to
risperidone under due to under under under after later also olanzapine improve
CMHT non- CMHT CMHT CMHT 6 weeks interrupted
compliance
a Comorbidity includes associated psychiatric and nonpsychiatric clinical conditions.
b Aripiprazole treatment of Patients nr 3 and nr 8 was discontinued after Week 3.
c Patients nr 7 and nr 10 were discharged home under the care of a CMHT after 6 weeks.
Abbreviations: BPRS, Brief Psychiatric Rating Scale; CMHT, community mental health team; WBC, white blood count.Neuropsychiatric Disease and Treatment 2006:2(2) 194
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patients also had a known history of alcohol or illicit
substance misuse, mostly cannabis abuse, while 3 patients
had an associated medical disorder. One patient suffered
from asthma and another was noticeably overweight. Patient
nr 8, who was known to be HIV-positive, complained of
persistent hypersalivation and was also grossly impaired by
dyskinetic movements, which were attributed to tardive
dyskinesia (TD). Most patients (n = 7) had been previously
treated with antipsychotics, whereas 3 had never received
any previous antipsychotic medication. All patients showed
moderate to severe psychotic symptoms on admission, as
reflected on their 48.8 ± 8.2 BPRS mean score at baseline
(n = 10; range 40–65).
Changes in BPRS scores indicated that most patients
(n = 7) responded to aripiprazole treatment (BPRS 20-point
reduction) within 4 weeks. A significant decrease in the
BPRS mean score to 35.4 ± 15.6 (n = 10; T9 = 3.96, p = 0.003)
was reached after patients had received aripiprazole for 2
weeks. Among the responders (n = 7), however, median time
to achieve response was 3 weeks. One patient who did
respond (nr 8) and another who did not (nr 3) had their
aripiprazole treatment discontinued after 3 weeks. At the
end of Week 4, BPRS mean score of the 8 patients who
completed at least 4 weeks of aripiprazole was 23.1 ± 17.5
(T7 = 5.89, p = 0.001), while BPRS mean score of the
6 responders who completed treatment was 16.0 ± 12.2
(T5 = 9.86, p = 0.0001).
Main therapeutic responses to aripiprazole treatment, as
perceived by the multidisciplinary team, included
amelioration of both positive and negative symptoms of
schizophrenia. Clinical changes in the responder group were
typically described as “paranoid, psychotic, and negative
symptoms resolved” and “improved social interaction”. No
incidents involving patients on aripiprazole were reported
by nursing staff at any time. Four of the 7 responders were
discharged from hospital within 6 weeks from the date of
admission. Two patients (nr 7 and nr 10) who had responded
within 4 weeks, but were still clinically unwell after 6 weeks
(BPRS > 20), remained in hospital for a few additional weeks
before a further delayed response to aripiprazole treatment
was achieved and they were considered fit for discharge.
Treatment of Patient nr 8 was discontinued after 3 weeks,
by which time he had already responded to treatment. Of
note, Patient nr 8 was observed to experience a significant
attenuation of his dyskinetic movements following
aripiprazole treatment. On admission, his speech and
mastication were both grossly impaired by sudden, severe,
involuntary oro-mandibular movements. Moreover, he was
unable to remain seated or still because of frequent and wide
jerky movements of trunk and limbs. Two weeks after he
was commenced on aripiprazole, his dyskinetic movements
had remarkably diminished, to the point that he could engage
in lengthy interviews, eat properly, and join occupational
therapy.
Eight patients were prescribed other drugs in addition
to aripiprazole. In most cases, this was lorazepam as required
for sedation (n = 6), but patients on aripiprazole did not
require lorazepam tranquilization any more frequently or at
higher doses than patients receiving other antipsychotic
medication. One patient with a history of alcohol abuse (nr 2)
received vitamin B as a dietary supplement and Patient nr 8
was prescribed hyoscine hydrobromide to mitigate his
preexisting hypersalivation. None of the patients on
aripiprazole required anticholinergic drugs to treat EPS.
Adverse reactions to aripiprazole were noted in 3 patients.
One patient developed mild perioral involuntary movements
that subsided spontaneously after a few days (nr 5) and
another complained of drowsiness after his dose of
aripiprazole was increased from 15 mg to 30 mg daily (nr
7). Aripiprazole treatment of Patient nr 8 was discontinued
at the end of Week 3 after blood tests revealed a drop in his
white blood cell count (WBC), specifically in the neutrophils
count. Similar drops in his WBC had happened on previous
occasions following courses of treatment using risperidone
and olanzapine.
The 3 nonresponders included 1 patient who complied
poorly with oral medication (nr 3), and who was switched
after 3 weeks to intramuscular depot injections of a
conventional antipsychotic, and 2 patients who did comply
with aripiprazole treatment for 4 weeks but failed to respond,
both of whom were later switched to alternative atypical
antipsychotics (nr 1 and 9). Patient nr 1 eventually responded
to oral treatment using risperidone while Patient nr 9
responded to olanzapine.
Discussion
Clinical trials of acutely psychotic patients lasting up to 6
weeks have shown that, relative to placebo, aripiprazole was
as effective as haloperidol and risperidone in the treatment
of psychotic symptoms (Kane et al 2002; Marder et al 2003;
Potkin et al 2003). However, the efficacy that antipsychotic
treatments may show in randomized controlled trials may
not always translate into their effectiveness in everyday
clinical practice. Away from the controlled conditions of
the research setting, in the hard-pressed environment of acute
psychiatric wards, clinical audits offer a practical tool toNeuropsychiatric Disease and Treatment 2006:2(2) 195
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assess the risks and benefits of antipsychotic treatments
precisely where they need to be most effective (Dratcu et al
2003). Although this was a small study, to our knowledge it
is the first report on antipsychotic monotherapy using
aripiprazole under naturalistic conditions in an inner-city
acute psychiatric setting.
The clinical-demographic profile of our patient group
was fairly representative of the male population admitted
to inner-city acute wards for treatment of psychotic
disorders. Patients had a median age of 36 years, most had
been ill for some years, most had been previously treated
with antipsychotics and admitted to hospital, and half of
the group had a confirmed associated history of substance
abuse. Except for one patient (nr 3), those who had not been
admitted before were the youngest of the group. All patients
were markedly psychotic at the time of admission.
Most patients responded to therapeutic doses of
aripiprazole within 4 weeks. Although a significant decrease
of psychotic symptoms was detected after 2 weeks, the
median time was 3 weeks for a therapeutic response (defined
as a 20-point decrease from pretreatment BPRS score) in
those who responded to treatment. The rate of response
(70%) to aripiprazole in this study was similar to that
reported elsewhere (eg, Kasper et al 2003), yet it surfaced
within a timeframe that was compatible with the constraints
of our acute setting. Symptom amelioration, which involved
both positive and negative symptoms of schizophrenia, was
corroborated independently by the clinical team and also
by the fact that most responders could be safely discharged
within 6 weeks from admission and the remainder a few
weeks later, following a further delayed response to
aripiprazole treatment.
One unexpected therapeutic response to aripiprazole was
the conspicuous improvement within 2 weeks of the severe
dyskinetic movements in 1 patient who suffered from TD.
TD, an iatrogenic syndrome that is deemed irreversible, has
been ascribed to denervation hypersensitivity in the
nigrostriatal pathway following long-term blockade of
postsynaptic D2 dopamine receptors by antipsychotics
(Tamminga and Woerner 2002). Dyskinetic movements may
arise from the ensuing excessive presynaptic release of
dopamine combined with hypersensitive postsynaptic D2
receptors. The attenuation of dyskinetic movements
following aripiprazole treatment may be associated with the
drug’s partial agonism at dopamine D2 receptors (Burris et
al 2002). In the presence of excessive dopamine availability,
as presumably is the case with the nigrostriatal pathway in
patients with TD, aripiprazole is likely to have antagonistic
effects on dopaminergic transmission. Unlike dopamine
antagonists, aripiprazole may restore more functional levels
of dopaminergic activity because its antagonistic action is
dependent on the availability of dopamine itself. If so,
arguably the partial D2 antagonism of aripiprazole could
also be of benefit in other disorders where, such as in TD
and schizophrenia, dopamine dysfunction is also thought
to play a role. Indeed, aripiprazole treatment has been
previously reported to improve symptoms not only of TD
(Duggal 2003) but also of Tourette syndrome (Kastrup et al
2005), restless legs syndrome (McLean 2004), Asperger
disorder (Staller 2003), and obsessive–compulsive disorder
(Connor et al 2005).
Most patients receiving aripiprazole required coprescrip-
tion of lorazepam for sedation, but lorazepam was not used
any more frequently or at higher doses than in patients
receiving other atypical antipsychotics. Moreover, as no
incidents on the ward were reported involving patients
treated with aripiprazole, its use to treat acutely psychotic
patients proved acceptable to our (originally slightly
skeptical) clinical team. Coprescription of lorazepam was
gradually discontinued without complications in the patients
who responded to aripiprazole treatment, all of whom were
discharged on aripiprazole monotherapy.
None of the patients receiving aripiprazole required
anticholinergic drugs to treat EPS. This is consistent with
results of randomized controlled studies of aripiprazole
treatment in patients with schizophrenia, which described
an incidence of EPS with aripiprazole similar to that with
placebo (Kasper et al 2003; Pigott et al 2003). However,
1 patient in this study experienced mild and transient perioral
involuntary movements that subsided spontaneously,
perhaps a reminder that some patients may be susceptible
to aripiprazole-induced EPS (Mendhekar 2004; Cohen et
al 2005; Sajbel et al 2005) and, probably far more rarely,
neuroleptic malignant syndrome (Chakraborty and Johnston
2005). One patient complained of drowsiness after his daily
dose of aripiprazole was increased from 15 mg to 30 mg, a
transient reaction that might be related to aripiprazole’s
pharmacological affinity for serotonin receptors (McGavin
and Goa 2002).
Aripiprazole treatment was discontinued in Patient nr 8
when he was found to have developed neutropenia after
3 weeks. The patient had had similar drops in WBC in the
course of previous antipsychotic treatments using
risperidone and olanzapine, respectively, so that this
hematological reaction was unlikely to be specific to
aripiprazole. His WBC normalized following drugNeuropsychiatric Disease and Treatment 2006:2(2) 196
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withdrawal but neutropenia was detected once again after
he was restarted on oral risperidone. Both conventional and
atypical antipsychotics have been associated with
neutropenia and agranulocytosis, with clozapine bearing the
strongest association (Alvir et al 1993), but a MEDLINE
search has shown not a single report on the association of
aripiprazole with either blood dyscrasia. Yet Patient nr 8
was HIV-positive, although he had never received any
antiretroviral therapy. Moreover, apart from his TD and
hypersalivation, his physical status on admission was good.
It is possible that the patient’s HIV-positive status made him
vulnerable to antipsychotic-induced neutropenia, regardless
of the antipsychotic used, aripiprazole being no exception.
If so, this finding may serve as a warning to clinicians about
specific problems associated with the pharmacological
management of psychosis in people who are HIV-positive.
However, it could also be an indication that, like other
antipsychotics, aripiprazole may also induce neutropenia
in some patients, regardless of their HIV status, a risk that
can only be determined should further similar cases be
reported.
Of the 3 patients who failed to respond, 1 did not comply
with oral medication and his response to aripiprazole could
not actually be established (nr 3). His symptoms improved
after he was started on intramuscular injections of a depot
antipsychotic. Reluctance to accept oral tablets of
antipsychotics is far from uncommon in psychotic patients,
in which case clinicians may resort to alternative
formulations, but at present aripiprazole is available only
as an oral tablet. The 2 other nonresponders were,
paradoxically, the eldest (nr 1) and the youngest (nr 9)
patients of the group, aged 50 and 19 years, respectively,
whose illness had the longest and the shortest duration, and
who had the highest (n > 10) and the lowest (n = 0) number
of previous admissions. Whether this warrants further
interpretation, the possibility that both might have responded
to aripiprazole treatment had they received it for more than
4 weeks cannot be excluded. Yet patients with schizophrenia
who fail to respond to one atypical antipsychotic may
respond to another drug of this class (NICE 2002). Patient
nr 1, who had been ill for decades, eventually responded to
risperidone, while Patient nr 9, who suffered from a first-
onset psychosis, responded to olanzapine.
In conclusion, we found that aripiprazole is an atypical
antipsychotic that can be safely and effectively used in the
acute hospital setting to treat actively psychotic patients with
schizophrenia. Aripiprazole treatment was well tolerated,
significantly ameliorated severe psychotic symptoms after
2–3 weeks and, although some patients had a delayed
response, all those who responded to it could be safely
discharged from hospital on aripiprazole monotherapy, most
of them within 6 weeks. Aripiprazole is currently available
for use only as an oral tablet preparation, which may restrict
its use in patients who are unwilling to comply with oral
treatment, but the few patients who failed to respond to
aripiprazole did respond to alternative antipsychotics.
Aripiprazole was not devoid of side effects, most of which
were mild and transient. Its mode of action as a partial
agonist at the dopamine D2 receptor may pose a risk of EPS
to some patients, but it may also prove of therapeutic use in
other disorders that are also associated with dopamine
dysfunction. In addition to psychiatric disorders other than
schizophrenia alone (Staller 2003; Barbee et al 2004; Connor
et al 2005), these may include TD and possibly other
extrapyramidal disorders as well. Finally, aripiprazole has
been marketed only relatively recently, and it may be some
time before the full extent of the risks and benefits associated
with its use becomes apparent. Clearly, further studies are
needed to investigate further potential indications for
aripiprazole. Along with postmarketing surveillance, they
can also help to ascertain the range of adverse reactions
that may be associated with aripiprazole treatment, including
the risk of drug-induced neutropenia.
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